Vaccine optimism, a calmer bond market, stimulus & Zoom in focus
Fiona Cincotta March 1, 2021 8:52 AM
US regulators approve JNJ vaccine boosting hopes of a quicker reopening. The bond market stabilises leaving US stimulus & Zoom earnings after the closing bell in focus.
Dow futures +1% at 31235
S&P futures +1% at 3848
Nasdaq futures +1.2% at 13070
FTSE +1.3% at 6568
Dax +0.9% at 13918
Euro Stoxx +1.3% at 3683
Stocks cheers the covid stimulus bill progress
US stock markets are pointing to a stronger start amid a calmer mood in the bond market and leaving the focus firmly on the US covid stimulus bill which was voted on in the House of Representatives over the week and now makes its way to the Senate where it is expected to be voted on next week.
Calmer bond market
After the bond market rout roiled financial markets last week, the picture is notably calmer this week. The 10 year US treasury yield continued to ease back from its spike higher to 1.6% last week to current levels of 1.43%.
However, speeches by Federal Reserve policymakers John Williams and Lael Brainard could well push the focus back on inflation expectations and the bond market.
Manufacturing PMIs in focus
The latest round of manufacturing PMIs have revealed broadly upbeat readings; China being the notable outlier. China’s Caixin PMI dropped to its lowest level in 9 months, although the market has shrugged off the figures given the likely distortion from the Lunar New Year.
Final PMI’s were upwardly revised across Europe with the Eurozone PMI recording its highest level since 2018 as demand surged.
US ISM manufacturing PMI is due at 15:00 UTC.
FDA approves Johnson & Johnson vaccine
Reopening optimism is adding to the upbeat mood after the US regulators approve the Johnson & Johnson one shot covid vaccine. This is the third vaccine to receive approval stateside and has the potential to speed up the reopening process dramatically boosting risk sentiment.
One of the main beneficiaries of the pandemic has undoubtedly been Zoom. It’s share price has soared across the year from an IPO price of $36 in late 2019 and valuation of $9 billion to its current price of $370 and a valuation of $120 billion.
Revenue has also surged with Q3 seeing a 367% jump in revenue to $777.2 million, well ahead of the $694 million expected and significantly up from Q1 2020 revenues of just $328 million. The share price has been on the decline since late October’s all time high of $588 as the prospect of a successful vaccine rollout and economies reopening have raised fears that growth will slow. So guidance will be closely eyed. Expectations are for EPS $0.78c.
For further insight into watch to expect from Zoom click here.
FX – EUR shrugs off accelerating German inflation
The US Dollar is extending 0.6% gains from the previous week. US Dollar Index DXY +0.15% holding above 91.00.
EUR/USD – trades depressed versus the stronger USD despite German inflation accelerating in February. German CPI February jumped 1.7% vs 1% Jan and 1.2% expected. The ECB weekly bond purchases are awaited.
Analyst Fiona Cincotta looks at EU/USD price action and levels to watch.
GBP/USD trades -0.20% at 1.3906
EUR/USD trades -0.25% at 1.2045
Oil resumes uptrend
Oil along with other risk assets is on the rise at the start of the week owing to the upbeat market mood. Investors continue to cheer the ongoing economic recovery and the prospect of a vaccine led reopening of the economy.
Iran’s rejection of the EU and US’s invitation for direct nuclear talks is also underpinning the price. Iran refuses to restart talks without the US first halting sanctions.
Attention will turn to this week’s OPEC+ meeting with chatter surrounding a production hike increasing.
US crude trades +2% at $62.25
Brent trades +0.4% at $64.81
14:30 Markit Manufacturing PMI
15:00 ISM manufacturing PMI
15:00 Construction spending
16:10 ECB Lagarde Speech
Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.
Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.